Bispecific DLL3-targeting T-cell engagers such as tarlatamab have improved outcomes in extensive-stage small-cell lung cancer (ES-SCLC), but clinical factors and early imaging cannot distinguish transient from durable benefit.
This study evaluated whether baseline CT radiomic texture and Quantitative Vessel Tortuosity (QVT) features, combined into a radiomic risk score, predict progression-free and overall survival in 50 ES-SCLC patients receiving tarlatamab after front-line chemoimmunotherapy at Cleveland Clinic.
The score independently stratified survival, pointing to a noninvasive tool for patient selection in a setting with limited options.
Read the full abstract HERE.
